Emergent BioSolutions Inc. (EBS) Stock

NYSE: EBSBiopharmaceutical company developing vaccines and therapeutics for infectious diseases and other public health threats.

Emergent BioSolutions stock price chart

EBS stock quote & key statistics

Emergent BioSolutions earnings per share

Income →
Earnings per share

Emergent BioSolutions revenue & net income

Income →
RevenueNet income

Emergent BioSolutions annual financials

Income statement →
Emergent BioSolutions Inc. revenue, net income and EPS by fiscal year
Fiscal yearRevenueNet incomeEPS
FY2025$742.9M$52.6M$1.50
FY2024$1.04B-$190.6M-$0.94
FY2023$1.05B-$760.5M-$10.08
FY2022$1.12B-$211.6M-$2.26
FY2021$1.77B$219.5M$6.00

Fiscal year ending December 31. Source: company filings via EODHD.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a leading life sciences company headquartered in Gaithersburg, Maryland, dedicated to providing preparedness and response solutions for a range of public health threats (PHTs) in the United States. Established in 1998, Emergent BioSolutions focuses on addressing accidental, deliberate, and naturally occurring threats such as chemical, biological, radiological, nuclear, and explosive incidents. The company's comprehensive portfolio includes products designed to combat emerging infectious diseases, support travel health, and manage acute and emergency care situations.

Among its key offerings, Emergent BioSolutions manufactures BioThrax, an anthrax vaccine widely used for biodefense purposes, and ACAM2000, a smallpox vaccine essential for national security preparedness. The company also produces Botulism Antitoxin Heptavalent to treat botulism, and raxibacumab for the treatment and prevention of inhalational anthrax. Additionally, Emergent BioSolutions provides medical countermeasures like Anthrasil for inhalational anthrax, as well as reactive skin decontamination lotion kits for chemical emergencies.

In response to public health needs, Emergent BiooSolutions developed NARCAN, a nasal spray used for emergency treatment of opioid overdose, highlighting its commitment to addressing the opioid crisis. The company also offers vaccines such as Vivotif for typhoid fever and Vaxchora for cholera, demonstrating its expertise in travel health and infectious disease prevention.

Emergent BioSolutions is actively advancing a robust pipeline of innovative products including AP003, a Naloxone multidose nasal spray for opioid overdose, and CGRD-001, a pralidoxime chloride/atropine auto-injector for nerve agent exposure. The company's commitment extends to contract development and manufacturing services, encompassing drug substance and product manufacturing, packaging, and technology transfer. With a steadfast focus on public health preparedness, Emergent BioSolutions continues to lead in providing critical solutions to mitigate and respond to evolving global health threats.

Emergent BioSolutions stock FAQ

What is the Emergent BioSolutions stock ticker symbol?

Emergent BioSolutions Inc. trades on the NYSE under the ticker symbol EBS.

What sector and industry is Emergent BioSolutions in?

Emergent BioSolutions Inc. is classified in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry.

How many employees does Emergent BioSolutions have?

Emergent BioSolutions Inc. has about 900 full-time employees.

What were Emergent BioSolutions's revenue and earnings last fiscal year?

Emergent BioSolutions reported revenue of $742.9M and net income of $52.6M in fiscal 2025, with earnings per share of $1.50. Revenue declined 28.8% from the prior year.

Is Emergent BioSolutions in the Russell 2000?

Yes. Emergent BioSolutions Inc. (EBS) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Emergent BioSolutions go public?

Emergent BioSolutions stock began trading on November 15, 2006.

Russell 2000 Drug Manufacturers - Specialty & Generic stocks

All Russell 2000 →